RKLB · Rocket Lab Corporation

The thesis

Rocket Lab's case is that revenue growth can absorb the share dilution that paid for the Iridium acquisition. The third-quarter 2026 report settles it. Revenue has to reach at least $250 million, the floor of the guidance issued on 10 August 2026, while the shares hold above a weekly close of $60.

The company has not dated that report. MarketBeat estimates 9 November 2026, after the close, and a smaller earnings-calendar site lists 10 November 2026. Either date falls just outside the next 30 days. Zacks Investment Research put consensus third-quarter revenue at $255.89 million on 5 October 2026, up 65% year over year and above the floor.

The narrative is maturing: Rocket Lab funded the acquisition on 15 September 2026, Iridium holders approved it on 24 September 2026, and since then the shares have moved on sector headlines rather than company results. On 8 October 2026 they fell 4.9% to a $68.40 close, according to MarketBeat. The trigger was the Federal Communications Commission (FCC) authorising SpaceX's direct-to-phone satellite network, and there was no Rocket Lab news that day.

Bullish and bearish views on Rocket Lab Corporation

The bull case on Rocket Lab Corporation (RKLB), in brief: Revenue growth is ahead of the test. The bear case: Margins are guided down into the test quarter.

Bull case

• Revenue growth is ahead of the test. Second-quarter 2026 revenue was $234.07 million, up 62% year over year, according to the 10 August 2026 release. Zacks' 5 October 2026 full-year 2026 revenue consensus is $945.03 million.
• Backlog keeps extending. Backlog was a record $2.36 billion at the end of the second quarter (10 August 2026). On 30 September 2026 Rocket Lab signed a 20-mission Electron deal with Synspective for 2028–2031, which brought that customer to 47 missions and total launch backlog past 100 missions.
• Acquisition funding is complete. Rocket Lab announced about $1.944 billion in gross equity proceeds from 29.3 million shares on 15 September 2026 and ended its $3.6 billion bridge commitment. Closing is expected by mid-2027, subject to regulatory approvals.
• Analyst targets sit well above the price. MarketBeat's 8 October 2026 tally shows 24 analysts with a Moderate Buy consensus and a $107.20 average target. Citi initiated at Buy with a $105 target on 1 October 2026, per StockAnalysis.
• Launch capacity elsewhere looks tight. Yahoo Finance reported on 6 October 2026 that at least seven spacecraft companies were told SpaceX's Falcon 9 is fully booked until 2028 or 2029. Bloomberg reported the same day that NASA is weighing a bulk purchase of launches for a Moon base, and the Federal Aviation Administration proposed streamlining commercial launch rules.

Bear case

• Margins are guided down into the test quarter. Third-quarter GAAP gross margin was guided to 29–31%, down from 36.1% in the second quarter. The 10 August 2026 guidance also calls for an adjusted EBITDA (earnings before interest, taxes, depreciation and amortisation) loss of $17–23 million.
• Neutron's schedule has slipped before. Spaceflight Now reported on 11 November 2025 that pad arrival had moved to the first quarter of 2026. The 10 August 2026 release tied pad delivery to the fourth quarter of 2026, and company news through 8 October 2026 carries no dated pad arrival.
• Insiders have been selling. SEC Form 4 filings show Chief Financial Officer Adam Spice sold 140,157 shares on 2 September 2026 at a $62.63 average. MarketBeat's 8 October 2026 summary also lists sales by executives Marvin Clevenger and Arjun Kampani over the past three months.
• More equity can be issued. A $3 billion at-the-market equity programme was filed on 20 May 2026. Sales under it show up in 10-Q, 8-K and 424B5 filings rather than press releases.
• Not every analyst is bullish. Piper Sandler initiated at Neutral with an $83 target on 16 July 2026. MarketBeat's 8 October 2026 count includes 5 Hold ratings and 1 Sell.

Price setup

The 8 October 2026 close of $68.40 is 54.5% below the 52-week high of $150.23. The shares are down 10.9% over three months on adjusted daily closes. MarketBeat put the 50-day moving average at $70.38 and the 200-day moving average at $84.43 on 8 October 2026, so the price sits below both.

The 14-day relative strength index (RSI) is 56.2, which is neither stretched nor washed out. Volume on 8 October 2026 was 22.15 million shares, slightly below the 23.08 million daily average MarketBeat reports. The $62.63 average price of the CFO's 2 September 2026 sale is the nearest dated reference below the market, and $60 sits under it.

On crowding, retail attention is heavy: Benzinga ran same-day articles explaining the share moves on 2 October 2026, 10-05, 10-06 and 10-07, and flagged large options trades on 2 October 2026 and 10-06. There is no wide gap above a rising moving average. Recent insider selling and the open at-the-market programme are the visible supply. The Iridium collar's $67.50 lower bound is close to the current price, but that ten-day price reference is set at closing in 2027, not now.

Catalysts, next 30 days

• No company-dated event falls inside the next 30 days. Rocket Lab usually announces its results date about two weeks ahead, and the coming weeks bring launches, contracts and sector moves.
• ~9 November 2026, est. (MarketBeat; one calendar lists 10 November 2026). Third-quarter 2026 results. They show whether revenue clears $250 million and whether gross margin stays within the 29–31% guide.
• Fourth quarter 2026 (company target). Neutron delivered to the pad at Launch Complex 3, Wallops Island. If no dated pad arrival comes with the third-quarter report, a 2027 first flight becomes more likely.
• Mid-2027 (company estimate; outside date 28 June 2027). Iridium closing, subject to regulatory approvals.

What would change the view

The case breaks if third-quarter 2026 revenue comes in below the $250 million guidance floor, or if GAAP gross margin falls below 29%. Either result would mean operating growth is not keeping pace with the share count. A company statement moving Neutron's pad delivery or first flight out of 2026 would remove the catalyst analysts cite most. A regulatory order blocking the Iridium deal, or a termination filing, would break the acquisition part of the case.

On price, a weekly close below $60 would put the shares under the CFO's $62.63 sale price and below every dated reference since September. Revenue above the $265 million top of guidance, together with a dated Neutron pad arrival, would strengthen the case.

What it trades with

The shares trade with the space group and react to SpaceX news more than to their own. On 6 October 2026 reports of Falcon 9 being fully booked and of a NASA bulk launch purchase lifted them. On 8 October 2026 the FCC approval of SpaceX's direct-to-phone system pulled them down 4.9%, while 24/7 Wall St. reported AST SpaceMobile down 7%, Planet Labs down 5% and the Procure Space ETF down 3%. The five-year beta of 2.63 means market-wide risk-off days hit harder. The defense and aerospace ETF XAR had a seven-week losing streak as of 29 September 2026.